translation agency

NLM AIDSLINE
The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS.
Kemper CA; Havlir D; Haghighat D; Dube M; Bartok AE; Sison JP; Yao Y;
September 30, 1994
J Infect Dis. 1994 Jul;170(1):157-64. Unique Identifier : AIDSLINE

The individual antibacterial activities of clofazimine, ethambutol, and rifampin in the treatment of Mycobacterium avium complex bacteremia in patients with AIDS were determined. Sixty human immunodeficiency virus 1-infected patients who had at least one blood culture positive for M. avium complex were randomized to receive either clofazimine (200 mg), ethambutol (15 mg/kg), or rifampin (600 mg) once daily for 4 weeks. Only ethambutol resulted in a statistically significant reduction in the level of mycobacteremia. The median change in individual baseline colony counts was -0.60 log10 cfu/mL after 4 weeks of ethambutol (P = .046). In contrast, median changes in individual baseline colony counts were -0.2 log10 cfu/mL and +0.2 log10 cfu/mL for clofazimine and rifampin, respectively (both, P > .4). Ethambutol had greater antibacterial activity, as determined by changes in the level of mycobacteremia, than either rifampin or clofazimine, supporting its continued use in combination with other agents in the treatment of M. avium infection.

Adolescence Adult AIDS-Related Opportunistic Infections/*DRUG THERAPY Bacteremia/COMPLICATIONS/*DRUG THERAPY/MICROBIOLOGY Clofazimine/ADVERSE EFFECTS/*THERAPEUTIC USE Ethambutol/ADVERSE EFFECTS/*THERAPEUTIC USE Female Human Male Microbial Sensitivity Tests Middle Age Mycobacterium avium-intracellulare Infection/COMPLICATIONS/*DRUG THERAPY Rifampin/ADVERSE EFFECTS/*THERAPEUTIC USE Support, Non-U.S. Gov't CLINICAL TRIAL JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIAL

www.aegis.org